Frontier Medicines Corporation

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
FMC-376Phase 1/2Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor …
Est. primary completion 2027-10 · NCT06244771 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
FMC-376Phase 1/2Locally Advanced Solid Tumor
Est. primary completion 2029-01 · NCT07944092 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.